Is there a Title Role for Renal Sympathetic Denervation in Patients with Symptomatic Myocardial Bridging Refractory to Clinical Treatment and Ventricular Arrhythmias?

Marcio Galindo Kiuchi, Shaojie Chen

Abstract


The connection concerning the autonomic nervous system and coronary spasm during the systole is multifaceted. An augmentation in sympathetic activity, due to pain caused by angina and the several transient ischemic episodes may origin an augment in noradrenaline, the neurotransmitter of efferent sympathetic fibers, triggering more vasoconstriction by stimulating vascular smooth muscle cells, besides may lead the cardiac hypertrophy. Based on these concepts we aim to find a role to renal sympathetic denervation in patients with symptomatic myocardial bridging refractory to standard clinical treatment and ventricular arrhythmias. In conclusion, our findings suggest that RSD can be a role in myocardial bridging treatment, augmenting the LVEF, diminishing the LV mass and the number of transient ischemic segments measured by CMRI, besides to reduce the number of individuals presenting symptoms, the mean of NSVT recorded by 24-hour-Holter monitoring, and the number of patients with SVT inducible by the EPS. Perhaps such benefits are due to the decrease in the LV mass and sympathetic cardiac activity, consequently, there being less constriction of the arteries with myocardial bridges and less ventricular arrhythmias.

We report preliminary data on 6 patients with controlled hypertension, with normal renal function, with symptomatic myocardial bridging refractory to clinical treatment and ventricular arrhythmias who underwent a pilot renal sympathetic denervation (RSD) procedure. At baseline, the 6 (100%) patients presented symptoms while 6 months after RSD only 1 (17%) subject still complained of the symptoms (P=0.0152). Our findings suggest that RSD can play a role in myocardial bridging treatment, augmenting LVEF, diminishing LV mass and the number of transient ischemic segments measured by CMRI.

 


Full Text:

PDF

References


Reyman HC. Disertatio de vasis cordis propriis. Bibl Anat. 1737; 2:359–379.

Angelni P, Velasco JA, Flamm S. Coronary anomalies: incidence, pathophysiology, and clinical relevance. Circulation. 2002; 105:2449–2454. DOI: https://doi.org/10.1161/01.CIR.0000016175.49835.57.

Rossi L, Dander B, Nidasio GP, et al. Myocardial bridges and ischemic heart disease. Eur Heart J. 1980; 1:239–245. DOI: http://dx.doi.org/ 239-245.

Tauth J, Sullebarger JT. Myocardial infarction associated with myocardial bridging: case history and review of the literature. Cath Cardiovasc Diagn. 1997; 40:364–367.

Yano K, Yoshino H, Taniuchi M, et al. Myocardial bridging of the LAD in acute inferior wall myocardial infarction. Clin Cardiol. 2001; 24:202–208. DOI: 10.1002/clc.4960240306.

Erbel R, Ge J, Mohlenkamp S. Myocardial bridging: a congenital variant as an anatomic risk factor for myocardial infarction? Circulation. 2009; 120:357–359. DOI: 10.1007/s12350-010-9303-6.

Marchionni N, Chechi T, Falai M, Margheri M, Fumagalli S. Myocardial stunning associated with a myocardial bridge. Int J Cardiol. 2002; 82:65–67. DOI: http://dx.doi.org/10.1016/S0167-5273(01)00580-0.

Feld H, Guadanino V, Hollander G, Greengart A, Lichstein E, Shani J. Exercise-induced ventricular tachycardia in association with a myocardial bridge. Chest. 1991; 99:1295–1296. DOI: http://dx.doi.org/10.1378/chest.99.5.1295.

Den Dulk K, Brugada P, Braat S, Heddle B, Wellens HJ. Myocardial bridging as a cause of paroxysmal atrioventricular block. J Am Coll Cardiol. 1983; 1:976–969. DOI: http://dx.doi.org/10.1016/S0735-1097(83)80218-6.

Tio RA, Van Gelder IC, Boonstra PW, Crijns HJ. Myocardial bridging in a survivor of sudden cardiac near-death: role of intracoronary Doppler flow measurements and angiography during dobutamine stress in the clinical evaluation. Heart. 1997; 77:280–282. DOI: 10.1136/hrt.77.3.280

Cutler D, Wallace JM. Myocardial bridging in a young patient with sudden death. Clin Cardiol. 1997; 20:581–583. DOI: 10.1002/clc.4960200614.

Mohlenkamp S, Hort W, Ge J, Erbel R. Update on myocardial bridging. Circulation. 2002; 106:2616–2622. DOI: 10.1007/s12350-010-9303-6.

Schwarz ER, Klues HG, vom Dahl J, Klein I, Krebs W, Hanrath P. Functional, angiographic, and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: effect of short-term intravenous beta-blocker medication. J Am Coll Cardiol. 1996; 27:1637–1645. DOI: http://dx.doi.org/10.1016/0735-1097(96)00062-9.

Nair CK, Dang B, Heintz MH, Sketch MH. Myocardial bridges: effect of propranolol on systolic compression. Can J Cardiol. 1986; 2:218–221.

Alessandri N, Dei Giudici A, De Angelis S, Urciuoli F, Garante MC, Di Matteo A. Efficacy of calcium channel blockers in the treatment of the myocardial bridging: a pilot study. Eur Rev Med Pharmacol Sci. 2012; 16:829–834.

Lee MS, Chen CH. Myocardial Bridging: An Up-to-Date Review. J Invasive Cardiol. 2015;27:521-8.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.

Kiuchi MG, E Silva GR, Paz LM, Chen S, Souto GL. Proof of concept study: renal sympathetic denervation for treatment of polymorphic premature ventricular complexes. J Interv Card Electrophysiol. 2016;47:221-229. DOI: 10.1007/s10840-016-0146-1.

Kiuchi MG, Chen S, Hoye NA. Renal sympathetic denervation for normotensive patients with recurrent mixed reflex syncope (the pilot RELAX study). J Integr Cardiol. 2016; 3: 1-8. DOI: 10.15761/JIC.1000202.

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4.




DOI: https://doi.org/10.17987/icfj.v12i0.430

Copyright (c) 2018 The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.